From: mdanderson.org FGFR inhibitor gains FDA approval based on 40% response rate in MD Anderson-led Phase II trial Treatment with the FGFR inhibitor erdafitinib in patients with metastatic bladder cancers marked by mutations in the FGFR3 gene resulted in a 40% overall response rate (ORR) and was well-tolerated, according to an international Phase II trial led by The University of …
First-in-Class Drug Preserves Blood Counts During Chemotherapy for Lung Cancer
By: Beth Fand Incollingo From: curetoday.com Given with each dose of chemotherapy, administration of trilaciclib may temporarily put bone marrow to sleep, helping to prevent fevers, infections and hospital stays in patients with small cell lung cancer, according to study findings presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. Side effects from chemotherapy often include nausea, …
Ongoing Study Will Examine Cardiac Toxicity of Breast Cancer Treatment
By: Brielle Benyon From: curetoday.com Certain breast cancer treatments could lead to heart problems down the line though unanswered questions still remain, according to recent research presented at the 2019 American Society of Clinical Oncology Annual Meeting. “We see that about a third of women, after treatment ends, are still living with fatigue and reduced exercise capacity. That puts them …
Breast cancer gene mutation clinical trial to take place in Australia
By: Meagan Dillon and Leah MacLennan From: abc.net.au Breast cancer is a disease that predominantly impacts women, but it is not unheard of for men to also carry a rare genetic mutation that significantly increases the risk. Helen Hicks’s husband Tony Ransom is in that category — but the Adelaide couple will not know if the mutation has been passed …
Elios Therapeutics Announces Positive Top-Line Data from Phase IIb Study Evaluating TLPLDC, a Personalized Therapeutic Cancer Vaccine, in Patients with High-Risk Melanoma
From: PR Newswire ~ Results Show Treatment with the TLPLDC Vaccine Significantly Reduced the Risk of Disease Recurrence by 50 Percent Compared to Placebo in Patients with Stage III and IV Resected Melanoma Who Completed the Primary Vaccine Series ~ TLPLDC Continues to Demonstrate a Predictable and Well-Tolerated Safety Profile with No New Safety Signals Identified ~ Data Support Plans …
I-Mab Announces IND Approval for Its Proprietary TJC4, A Potentially Differentiated CD47 Antibody, to Initiate Clinical Trials in China
Source: I-MAB Pharma From: prnewswire.com I-Mab Biopharma (“I-Mab”), a clinical stage biotech company exclusively focusing on discovery and development of innovative biologics in immuno-oncology and autoimmune diseases, announces that the National Medical Products Administration (NMPA) has approved its investigational new drug (IND) application for TJC4, a differentiated fully human CD47 monoclonal antibody internally developed for the treatment of advanced malignant …
Lessons Learned in My Search for a Metastatic Cancer Clinical Trial
By: Sarah DeBord From: curetoday.com Sarah DeBord was diagnosed with metastatic colon cancer at age 34. In the years since, she has turned her diagnosis into a calling, and become an advocate for other young adults diagnosed with colorectal cancer and parents with young families facing cancer. She works as a communications and program manager for the Minneapolis-based Colon Cancer …
Backed by Dana-Farber research, FDA approves new drug combination for treating advanced kidney cancer
Source: dana-farber.org From: Redington Life Sciences News An immunotherapy drug combination whose clinical testing was co-led by Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, has become a standard first-line therapy for patients with metastatic kidney cancer. The drug combination of the immunotherapy drug avelumab (BAVENCIO) plus axitinib (INLYTA), a VEGF targeted agent, was approved today by the U.S. Food …
Phase III Shows Benefit With Olaparib in Platinum-Sensitive BRCA+ Relapsed Ovarian Cancer
By: Danielle Ternyila From: targetedonc.com According to topline findings from the multicenter, open-label, phase III SOLO3 trial, the overall objective response rate (ORR) was 72% with single-agent olaparib (Lynparza) versus 51% with chemotherapy in patients with platinum-sensitive, relapsed, germline BRCA-mutant ovarian cancer who were previously treated with at least 2 chemotherapy regimens. Further, in patients with only 2 prior lines …
Immutep Completes Patient Enrolment of the AIPAC Phase IIb Clinical Trial in Metastatic Breast Cancer
Source: GLOBE NEWSWIRE From: yahoo.com 226 patients with metastatic breast cancer have been enrolled in the AIPAC study Combination of eftilagimod alpha, an antigen presenting cell (APC) activator, administered in combination with chemotherapy is designed to boost the T-cell immune responses against tumours Read-out of progression-free survival (PFS) primary endpoint expected to occur in Q1 of calendar year 2020 Immutep …